Development of chemotherapeutics for unresectable advanced esophageal cancer. Issue 12 (1st December 2020)

• Record Type: Journal Article
• Authors: Imazeki, Hiroshi; Kato, Ken
• Is Part Of: Expert review of anticancer therapy. Volume 20:Issue 12(2020)
• Page Start: 1083
• Page End: 1092
• Publication Date: 2020-12-01
• Subjects: Esophageal squamous cell carcinoma -- cytotoxic agent -- molecular-targeted agent -- immune checkpoint inhibitor; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2020.1814149
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction: The prognosis of unresectable advanced esophageal squamous cell carcinoma (ESCC) has gradually improved due to efforts for the development of systemic chemotherapy or concurrent chemoradiotherapy. Areas covered: Chemotherapeutic agents such as cytotoxic agents, molecular-targeted agents, and immune checkpoint inhibitors, sometimes used with irradiation, lead in the treatment of unresectable advanced ESCC. Here, we review the latest treatment strategies for unresectable advanced ESCC and discuss future perspectives. Expert opinion: Immunotherapeutic agents will be part of the treatment of unresectable advanced ESCC in the near future. However, definitive predictive biomarkers to determine good patient candidates remain unclear for immunotherapy in patients with ESCC. Further research is warranted to identify those biomarkers working individually and in combination. Moreover, genome-based therapeutics enable individualized and patient-specific treatment. The development of molecular-targeted drugs against actionable or druggable genes is in progress.